Exelixis vs Moderna (EXEL vs MRNA)
Side by side from their SEC filings: revenue, margins, growth, returns and valuation, plus short interest, insider activity and institutional ownership.
Exelixis is the larger company by revenue ($2.3B vs $1.9B). Moderna carries the larger market value ($61.6B vs $13.9B). Exelixis has grown revenue faster over the last 4 fiscal years (+61.7% cumulative vs -89.5%).
About Exelixis
Exelixis, Inc. is a biopharmaceutical company focused on developing and commercializing oncology medicines. Its main products include cabozantinib-based therapies marketed as CABOMETYX and COMETRIQ, which are approved to treat various forms of cancer such as renal cell carcinoma, hepatocellular carcinoma, thyroid cancer, and neuroendocrine tumors. The company serves patients and healthcare providers by advancing cancer treatment options through its internal research and strategic collaborations.
About Moderna
Moderna, Inc. develops medicines based on messenger RNA (mRNA) technology to treat and prevent diseases. Its main products include COVID-19 vaccines Spikevax and mNEXSPIKE, and the respiratory syncytial virus vaccine mRESVIA. The company serves patients globally and is advancing a pipeline of vaccines and therapies for infectious diseases, oncology, and rare diseases.
Head to head (EXEL FY2025 vs MRNA FY2025)
| Metric | EXELFY2025 | MRNAFY2025 |
|---|---|---|
| Revenue | $2.32B | $1.94B |
| Revenue growth (YoY) | 7.0% | -39.9% |
| Gross margin | — | — |
| Operating margin | 37.6% | — |
| Net margin | 33.7% | — |
| Net income | $782.6M | $-2.82B |
| Diluted EPS | $2.78 | $-7.26 |
| FCF margin | 37.7% | — |
| ROE | 36.2% | -32.6% |
| Long-term debt / equity | — | 0.07× |
| Market cap | $13.90B | $61.59B |
| P/E | 17.8× | — |
Fundamentals are from each company’s SEC filings (EXEL FY2025, MRNA FY2025). ROE is net income over fiscal-year-end equity; long-term debt / equity counts non-current term debt only. P/E and market cap are derived from stored market prices, last retrieved on a rolling basis and typically within the past week.
Five-year trend (as reported)
| EXEL by fiscal year | FY2020 | FY2021 | FY2022 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $1.43B | $1.61B | $1.83B | $2.17B | $2.32B |
| Net income | $231.1M | $182.3M | $207.8M | $521.3M | $782.6M |
| Operating margin | 20.0% | 12.5% | 9.3% | 27.9% | 37.6% |
| MRNA by fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $18.47B | $19.26B | $6.85B | $3.24B | $1.94B |
| Net income | $12.20B | $8.36B | $-4.71B | $-3.56B | $-2.82B |
| Operating margin | 72.0% | 48.9% | -61.9% | — | — |
Exelixis and Moderna use different fiscal calendars (EXEL's FY2025 ended 2026-01-02, MRNA's FY2025 ended 2025-12-31), so their fiscal years are shown separately rather than forced into one timeline.
Peer standing
Where each company ranks among the 71 biotech companies, on the same scale. Each figure is ranked only against peers that report it. Percentiles describe position in the distribution, not a rating.
| Metric | EXEL | MRNA |
|---|---|---|
| Revenue growth (YoY) | +7.0%40th percentile of 64 | -39.9%14th percentile of 64 |
| ROE | 36.2%92nd percentile of 61 | -32.6%47th percentile of 61 |
| Short interest (days to cover) | 8.71d54th percentile of 71 | 9.15d60th percentile of 71 |
Short interest
| FINRA settlement data | EXEL | MRNA |
|---|---|---|
| Shares sold short | 28.0M | 52.8M |
| Change vs prior settlement | -2.5% | +6.1% |
| Days to cover | 8.71 | 9.15 |
| As of settlement | 2026-08-14 | 2026-08-14 |
Source: FINRA Consolidated Short Interest. FINRA is the owner and source of the FINRA-supplied data; republishing or redistributing it is not permitted. Not presented as a percentage of float. No FINRA endorsement of this product is implied.
Insider activity (last 90 days)
| Form 4 activity (codes P/S) | EXEL | MRNA |
|---|---|---|
| Buys | 0 | 0 |
| Sells | 1 ($526,512) | 7 ($35.2M) |
Non-derivative purchases (code P) and sales (code S) reported on SEC Form 4, which may be open-market or private (grants, exercises and tax withholding excluded). For context, about 15% of covered companies saw any reported insider purchase (code P) in a 90-day window.
Held by the same investors
6 tracked 13F managers hold both Exelixis and Moderna as of their latest quarterly filings: AQR Capital Management, Bridgewater Associates, Citadel Advisors, D. E. Shaw, Millennium Management, Two Sigma Investments. See which superinvestors hold your own portfolio with the smart money checker.
Go deeper
AMGN vs EXELBIIB vs EXELEXEL vs GILDEXEL vs NBIXEXEL vs RVMDEXEL vs TECHAll biotech stocks →All comparisons →
Track EXEL and MRNA
Get an alert when either company files something material, see which superinvestors own them, and ask their filings a question with cited answers.
Start monitoring freeIncludes one free filing-grounded research answer. Or check your whole portfolio, no account needed.
Data sourced from SEC EDGAR. Figures are as-reported and may be unaudited or restated; verify against the source filings before relying on them. Comparisons are descriptive (higher or lower on a reported figure), not a rating or a recommendation. Informational only. Not investment advice.